John C Boik

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study
    John C Boik
    Graduate School of Biomedical Sciences, University of Texas, Houston, TX, U S A
    Stat Med 27:1040-61. 2008
  2. pmc Structure-activity models of oral clearance, cytotoxicity, and LD50: a screen for promising anticancer compounds
    John C Boik
    Department of Experimental Therapeutics, University of Texas M, d, Anderson Cancer Center, 8000 El Rio, Houston, TX 77054, USA
    BMC Pharmacol 8:12. 2008
  3. pmc A classification model to predict synergism/antagonism of cytotoxic mixtures using protein-drug docking scores
    John C Boik
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
    BMC Pharmacol 8:13. 2008

Detail Information

Publications3

  1. ncbi request reprint Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study
    John C Boik
    Graduate School of Biomedical Sciences, University of Texas, Houston, TX, U S A
    Stat Med 27:1040-61. 2008
    ..The MixLow method can be used to quantify drug interactions in any fixed-ratio drug combination study that includes within-group and between-group replicates, and where responses follow a sigmoidal pattern...
  2. pmc Structure-activity models of oral clearance, cytotoxicity, and LD50: a screen for promising anticancer compounds
    John C Boik
    Department of Experimental Therapeutics, University of Texas M, d, Anderson Cancer Center, 8000 El Rio, Houston, TX 77054, USA
    BMC Pharmacol 8:12. 2008
    ..Multitask learning is particularly useful when the number of available training records is small relative to the number of features, as was the case with the oral clearance data...
  3. pmc A classification model to predict synergism/antagonism of cytotoxic mixtures using protein-drug docking scores
    John C Boik
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
    BMC Pharmacol 8:13. 2008
    ..Results were compared to models where explanatory variables were constructed using the pseudomolecule approach of Sheridan...